
|Articles|November 14, 2007
Approval for pain reliever for osteoarthritic knees to be delayed
Genzyme has to provide FDA with more data on Synvisc-One before the pain-relieving treatment for osteoarthritis can be approved.
Advertisement
Those who were waiting for the approval of Synvisc-One will have to wait a little longer. Genzyme Corp., which is applying for approval of the next generation of Synvisc (hylan G-F 20),
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Meeting at the Crossroads: The Role and Impact of PBMs and BOPs on Pharmacists
2
Pharmacies Adapting to IRA-Negotiated Drug Prices Despite Looming Financial Concerns
3
More Than 200 Organizations Denounce Childhood Vaccine Schedule Change
4
Adjunctive Lumateperone Maintains Remission Rates for Major Depressive Disorder
5









































































































































































































